Pfizer blueprints $200M R&D campus; Galapagos bags $50M milestone from Gilead

Pfizer is building a new R&D campus in St. Louis for more than 600 staffers currently deployed at two nearby locations. This new consolidation project will cost more than $200 million.

The Belgian biotech Galapagos and its partners at Gilead have dosed their first patient in a Phase III study of their closely-watched drug filgotinib for Crohn’s disease. Gilead, which has experienced a slate of clinical setbacks this year, is handing over a $50 million milestone to mark the start of the study.

Proteros biostructures GmbH has struck its second research agreement with Merck. The new collaboration is aimed at developing small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->